• Minoryx
    Minoryx
    Home
    Our Company
    Who we areManagement teamBoard of directorsScientific advisory boardFunding
    Our Science
    OverviewAdrenoleukodystrophyFriedreich's ataxia
    Our Programs
    OverviewLeriglitazone
    Clinical Studies
    Clinical Studies ADVANCEFRAMESNEXUSResourcesExpanded Access Policy
    Media
    Careers
    Follow us
    Contact
    Funding
    Home Our Company Funding
  • Private Investors
    Ysios Capital
    Health Equity
    Kurma Partners
    Chiesi Ventures
    Roche
    Caixa Capital Risc
    Eurazeo
    Fund+
    SRIW
    Sambrinvest
    sfpi
    Columbus Venture Partners CDTI Innvierte
    This company is capitalized by Innvierte, an investment program of CDTI, E.P.E.
  • Public Funds 
     
     
    Retos-Colaboración - 2017 (RTC-2017-5867-1)
                                   - 2019 (RTC-2019-6825-1)
    CDTI 2017 (IDI-20180106)
    Unión Europea - Fondo Europeo de Desarrollo Regional
    Minsiterio de Ciencia, innovación y universidades
    CDTI
  • Retos-Desarrollo - 2014 (RTC-2014-2412)
                              - 2016 (RTC-2016-5686)
    Innpacto 2012 (PT-2012-0561-010000)
    Torres Quevedo - 2012, 2013, 2014, 2015, 2017, 2018
    Ministerio de ciencia, innovación y universidades
  • AMMIC Project / RIS3CAT 2016-2020
    Generalitat de Catalunya
    Unión Europea - Fondo Europeo de Desarrollo Regional
  • RD14-1-0114 Desenvolupament MIN-102
    Acció Generalitat de Catalunya
  • Innovative SME
    Innovate SME
  • ENISA Jóvenes Emprendedores 2012
    Enisa
  • TECNIOspring PLUS

    Aquest projecte ha rebut finançament del programa de recerca i innovació Horitzó 2020 de la Unió Europea sota l'acord de subvenció Marie Skłodowska-Curie No 712949 (TECNIOspring PLUS), així com de l'Agència per a la Competitivitat de l'Empresa de la Generalitat de Catalunya

    Unión Europea
    Acció Generalitat de Catalunya
    Tecnio spring
  • The NEXUS trial received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No No. 822968
    Unión Europea
  • News
    See all
    Minoryx raises €51 million to support Marketing Authorization Application and launch preparations for X-linked Adrenoleukodystrophy (X-ALD) therapy
    May 31st, 2022
    Additional data from Minoryx’s Phase 2/3 ADVANCE clinical trial presented at American Neurological Association (ANA) 2021
    November 3rd, 2021
    Minoryx publishes mechanism of action of leriglitazone in X-ALD in Science Translational Medicine journal
    June 3rd, 2021
    Minoryx Phase 2/3 ‘ADVANCE’ study results to be presented at the 2021 American Neurological Association (AAN) Annual Meeting
    April 12th, 2021
    Minoryx presents topline results from Phase 2/3 “ADVANCE” study demonstrating significant clinical benefit of leriglitazone in adrenomyeloneuropathy (AMN)
    January 26th, 2021
    Minoryx’s clinical candidate leriglitazone shows clinical benefit in a proof of concept Phase 2 study in Friedreich´s ataxia
    December 15th, 2020
    Minoryx’s preclinical data for leriglitazone in Friedreich’s Ataxia published in Neurobiology of Disease Journal
    November 16th, 2020
    European Investment Bank provides Minoryx with up to €25 million to support development of breakthrough therapies in orphan neurodegenerative diseases
    October 30th, 2020
    Minoryx Therapeutics and Sperogenix Therapeutics enter into an exclusive license agreement to develop and commercialize leriglitazone in mainland China, Hong Kong and Macau
    September 23rd, 2020
    Minoryx Therapeutics doses first patient with leriglitazone in registration-enabling cALD NEXUS trial
    May 12th, 2020
  • Contact
    Headquarters
    https://www.minoryx.com/content/imgs/mail/logo.png
    Av. Ernest Lluch 32 - TCM3
    08302 Mataró
    (Barcelona) Spain
    info@minoryx.com 0034935441466+34 93 544 14 66
    Belgian R&D Site
    https://www.minoryx.com/content/imgs/mail/logo.png
    Rue Auguste Piccard 48, I - Tech Incubator
    6041 Gosselies
    (Charleroi) Belgium
    info@minoryx.com 003278700162+32 787 00 162
    Contact
    Follow us
    Legal Notice Privacy Policy Cookies Policy
    by eMascaró